CCK-resistance in Zucker obese versus lean rats.
Obese Zucker rats are less sensitive to the satiety effect of CCK than lean litter mates. The present studies further characterised this CCK resistance. Subcutaneous injection of the CCK agonist caerulein dose-dependently decreased food intake in Zucker obese and lean rats whereas the CCK-B agonist gastrin-17 did not. Caerulein at 4 microg/kg, which resulted in CCK plasma bioactivity slightly above postprandial levels, decreased food intake in lean rats but not in obese rats. The decrease in food intake was also more marked at higher caerulein doses (20-100 microg/kg) in lean versus obese rats. In lean animals the satiety effects of the "near physiological" 4 microg/kg caerulein dose was abolished after blockade of vagal afferents with capsaicin, whereas the effects of higher caerulein doses were not. CCK-stimulated amylase secretion from pancreatic acini and binding capacity of 125I-labelled CCK-8 were decreased in obese versus lean rats. The CCK-A antagonist loxiglumide at 20 mg/kg, a dose which abolished the action of all caerulein doses on food intake, failed to alter the food intake either in obese or in lean rats when given without an agonist. The results suggest that the satiety effects of "near physiological" doses of caerulein in lean rats are mediated by vagal afferents whereas pharmacological doses act via non-vagal mechanisms. The differences in CCK's satiety effect between lean and obese rats may be due to differences in CCK-receptor binding and action at peripheral vagal sites. However, the failure of the CCK-A antagonist to increase food intake questions whether any of the effects of exogenous CCK are of physiological relevance.
Niederau
C
C
Department of Medicine, Heinrich-Heine-University, Düsseldorf, Germany. claus.niederau@uni-duesseldorf.de
Meereis-Schwanke
K
K
Klonowski-Stumpe
H
H
Herberg
L
L
D000681:Amylases / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D002211:Capsaicin / Q000008:administration & dosage; D002766:Cholecystokinin / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004435:Eating / Q000187:drug effects; D005260:Female; D007279:Injections, Subcutaneous; D008297:Male; D009765:Obesity / Q000209:etiology* / Q000235:genetics / Q000503:physiopathology; D011377:Proglumide / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D011924:Rats, Zucker; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors / Q000187:drug effects
D011949:Receptors, Cholecystokinin; C053737:loxiglumide; D002766:Cholecystokinin; D000681:Amylases; D011377:Proglumide; D002211:Capsaicin